11 Jan 2019 Governance
Leukaemia UK and Leuka have merged
We are delighted to announce that on 1 November Leuka and Leukaemia UK merged, bringing together two of the UK’s leading leukaemia and blood cancer charities to create one charity dedicated to innovative research and care for people affected by blood cancers. The two charities have joined forces under the name Leukaemia UK, uniting Leuka’s 37 years’ experience in ground-breaking medical research with Leukaemia UK’s four decades of pioneering care.
From research to care, the new charity will continue to put people affected by blood cancers at its heart. Together, Leukaemia UK aims to carry out even more world-class research and advances in care.
Leukaemia UK will be led jointly by Leuka’s CEO Olive Boles and Leukaemia UK’s CEO Angela Smith-Morgan. The charity’s new Chair of Trustees is Chris Corbin, current Chair of Leuka, who is supported by a Board including both Leuka and Leukaemia UK Trustees.
Related posts
1 August 2022
New research could help detect leukaemia earlier in older people
New research findings, published in the scientific journal Nature Medicine, could help better predict risk of leukaemia in older people and ultimately improve early diagnosis of the disease. The research…
17 October 2022
New campaign launches for the forgotten 500,000 families
Patient groups, charities and clinicians unite to raise awareness of half a million vulnerable people, many of whose lives have never returned to normal after the Covid-19 lockdown. A new…
23 September 2022
Spectacular sailing challenge in memory of Pat Buckley
Royal Corinthian Yacht Club’s 61st Endeavour Trophy fundraiser for Leukaemia UK A fleet of thirty boats displaying the Leukaemia UK logo on their sails will put on a spectacular racing…
25 November 2025
Improving access to life-changing treatment – Leukaemia UK’s role in the approval of Aucatzyl
Today, NICE announced its recommendation for Aucatzyl (obecabtagene autoleucel), a CAR-T therapy, to be made available on the NHS for treating adults aged 26 and over with relapsed or refractory…